| Dr Shrinath Kalaseshwar Nadig, MD | |
|
116 Clarkesville Plz, Clarkesville, GA 30523-6216 | |
| (706) 680-6526 | |
| Not Available |
| Full Name | Dr Shrinath Kalaseshwar Nadig |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 43 Years |
| Location | 116 Clarkesville Plz, Clarkesville, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720009657 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | LL15881 (Oregon) | Primary |
| Entity Name | Clarkesville Dermatology & Medical Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346792538 PECOS PAC ID: 9739464496 Enrollment ID: O20170620000024 |
News Archive
Leukemia stem cells are rare cells that can renew themselves while continuing to generate malignant cells known as leukemic blasts. These cells are difficult to eradicate using chemotherapy drugs and frequently lead to recurrence of leukemia.
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.
Researchers are testing three promising new electromagnetic imaging techniques to help detect breast abnormalities, including cancer. The findings of the benchmark study will be published in the May issue of the journal Radiology.
Diagnosis of gastric cancer in the early stages is difficult because of the lack of simple and cheap methods of inspection and specific markers of gastric cancer while the symptoms of the disease are vague and tend to overlap with other common and benign conditions. Better tumor characterization and more individualized treatment planning can be expected only with the implementation of better diagnostic tools combined with advances in molecular and genetic analysis.
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).
› Verified 4 days ago
| Entity Name | Blue Ridge Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982380036 PECOS PAC ID: 3476996844 Enrollment ID: O20240213002637 |
News Archive
Leukemia stem cells are rare cells that can renew themselves while continuing to generate malignant cells known as leukemic blasts. These cells are difficult to eradicate using chemotherapy drugs and frequently lead to recurrence of leukemia.
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.
Researchers are testing three promising new electromagnetic imaging techniques to help detect breast abnormalities, including cancer. The findings of the benchmark study will be published in the May issue of the journal Radiology.
Diagnosis of gastric cancer in the early stages is difficult because of the lack of simple and cheap methods of inspection and specific markers of gastric cancer while the symptoms of the disease are vague and tend to overlap with other common and benign conditions. Better tumor characterization and more individualized treatment planning can be expected only with the implementation of better diagnostic tools combined with advances in molecular and genetic analysis.
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shrinath Kalaseshwar Nadig, MD 3248 Clarks Bridge Rd, Gainesville, GA 30506-3722 Ph: (503) 334-1856 | Dr Shrinath Kalaseshwar Nadig, MD 116 Clarkesville Plz, Clarkesville, GA 30523-6216 Ph: (706) 680-6526 |
News Archive
Leukemia stem cells are rare cells that can renew themselves while continuing to generate malignant cells known as leukemic blasts. These cells are difficult to eradicate using chemotherapy drugs and frequently lead to recurrence of leukemia.
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.
Researchers are testing three promising new electromagnetic imaging techniques to help detect breast abnormalities, including cancer. The findings of the benchmark study will be published in the May issue of the journal Radiology.
Diagnosis of gastric cancer in the early stages is difficult because of the lack of simple and cheap methods of inspection and specific markers of gastric cancer while the symptoms of the disease are vague and tend to overlap with other common and benign conditions. Better tumor characterization and more individualized treatment planning can be expected only with the implementation of better diagnostic tools combined with advances in molecular and genetic analysis.
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).
› Verified 4 days ago